ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

ADVFN

Trade Now

EasyMarkets
Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P 500
4,567.84
(
0.01%
)
US Tech 100
15,492.00
(
0.0%
)
Dow Jones
36,147.00
(
0.06%
)
Brent Oil
74.365
(
-3.48%
)
Bitcoin
44,046.93
(
-0.07%
)
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) News

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:EPRX
DateTimeSourceHeadlineSymbolCompany
11/14/20235:01PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
11/01/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of RheumatologyTSX:EPRXEupraxia Pharmaceuticals Inc
10/11/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
09/11/20233:32PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
09/07/20235:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Change of AuditorTSX:EPRXEupraxia Pharmaceuticals Inc
09/06/20235:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023TSX:EPRXEupraxia Pharmaceuticals Inc
08/18/20237:20PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125TSX:EPRXEupraxia Pharmaceuticals Inc
08/11/20235:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
08/04/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces a Non-Brokered Private Placement of up to C$22 MillionTSX:EPRXEupraxia Pharmaceuticals Inc
06/26/20237:00AMPR Newswire (US)Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
06/26/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
06/15/20236:42PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf ProspectusTSX:EPRXEupraxia Pharmaceuticals Inc
06/13/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Receives U.S. FDA Fast Track Designation for EP-104IAR in Treatment of OsteoarthritisTSX:EPRXEupraxia Pharmaceuticals Inc
06/08/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Doses First Patient in Phase 1b/2a Eosinophilic Esophagitis TrialTSX:EPRXEupraxia Pharmaceuticals Inc
05/25/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Last Patient Last Visit in Phase 2 Osteoarthritis Clinical Trial of EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
05/18/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical OfficerTSX:EPRXEupraxia Pharmaceuticals Inc
05/11/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
04/20/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
03/23/20235:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2022 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
12/07/20227:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee OsteoarthritisTSX:EPRXEupraxia Pharmaceuticals Inc
11/07/20227:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
11/01/20227:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Appoints Chief Business OfficerTSX:EPRXEupraxia Pharmaceuticals Inc
10/12/20227:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
10/11/20227:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
09/26/20227:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
09/07/20221:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at H.C. Wainwright Global Investment ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
08/12/20227:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
07/07/20225:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Recognized as Emerging Life Sciences Company of the Year by Life Sciences British ColumbiaTSX:EPRXEupraxia Pharmaceuticals Inc
06/08/20227:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at BIO International ConventionTSX:EPRXEupraxia Pharmaceuticals Inc
05/05/20225:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2022 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX

Your Recent History

USOTC
CRCW
Crypto (PK)
NASDAQ
BETS
Bit Brother
USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
CGAC
Code Green Apparel (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
ZHUD
Zhuding (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
TGGI
Trans Global (CE)
USOTC
NREG
Newregen (PK)
USOTC
GEGI
Genesis Electronics (PK)
USOTC
RDGL
Vivos (QB)
USOTC
CDSG
China Dongsheng (PK)
COIN
SHIBUSD
SHIBA INU
NASDAQ
PLUG
Plug Power
USOTC
AXXA
Exxe (PK)
USOTC
BLLB
Bell Buckle (PK)
Delayed Upgrade Clock
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com